Comparative investigation of basal insulin glargine versus metformin treatment in drug naive type 2 diabetes patients: results of the GLORY study

Aims: Type 2 diabetes (T2D) is characterised by progressive loss of beta cell capacity with glucotoxicity as a booster. Current strategy with metformin (MET) as first line drug fails to prevent disease progression. Preliminary data indicate that early use of insulin in the course of the disease might be able to preserve beta cell function. We investigated whether basal insulin treatment in recently diagnosed T2D patients can improve glucose control and preserve insulin secretion in comparison to MET. Methods: In this randomized, prospective 36-wk study 75 eligible patients (45m, 30 f, mean age 60.7±9.2 yr) with…